<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Leung HKM</submitter><pubmed_abstract>Colorectal cancer (CRC) is both a leading cause of cancer-related mortality and one of the most frequently diagnosed cancers. Previous studies have shown that zearalenone and theabrownin each exert anti-CRC effects. Here, we aimed to evaluate the anti-tumor properties of theabrownin and zearalenone mixture (TZ) and to assess whether supplementing TZ with 5-FU, a commonly used chemotherapeutic drug, could further suppress CRC tumorigenesis. Our results revealed that TZ significantly attenuated AOM/DSS-induced colorectal tumorigenesis. TZ improved survival rate, reduced tumor count, preserved colon length, and mitigated colonic inflammation in AOM/DSS mice. In addition, the concentration of pro-inflammatory cytokines IL-6, TNF-α and IL-17 A/F and proliferative PI3K/AKT were significantly red</pubmed_abstract><journal>Scientific reports</journal><pagination>26386</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12280149</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Theabrownin combined with zearalenone suppresses colitis-associated colorectal cancer by inhibiting PI3K/AKT pathway and enhancing microbial propionate production.</pubmed_title><pmcid>PMC12280149</pmcid><pubmed_authors>Zhang F</pubmed_authors><pubmed_authors>Lo EKK</pubmed_authors><pubmed_authors>Ismaiah MJ</pubmed_authors><pubmed_authors>Felicianna</pubmed_authors><pubmed_authors>El-Nezami H</pubmed_authors><pubmed_authors>Chen C</pubmed_authors><pubmed_authors>Leung HKM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Theabrownin combined with zearalenone suppresses colitis-associated colorectal cancer by inhibiting PI3K/AKT pathway and enhancing microbial propionate production.</name><description>Colorectal cancer (CRC) is both a leading cause of cancer-related mortality and one of the most frequently diagnosed cancers. Previous studies have shown that zearalenone and theabrownin each exert anti-CRC effects. Here, we aimed to evaluate the anti-tumor properties of theabrownin and zearalenone mixture (TZ) and to assess whether supplementing TZ with 5-FU, a commonly used chemotherapeutic drug, could further suppress CRC tumorigenesis. Our results revealed that TZ significantly attenuated AOM/DSS-induced colorectal tumorigenesis. TZ improved survival rate, reduced tumor count, preserved colon length, and mitigated colonic inflammation in AOM/DSS mice. In addition, the concentration of pro-inflammatory cytokines IL-6, TNF-α and IL-17 A/F and proliferative PI3K/AKT were significantly red</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-03-18T13:55:41.961Z</modification><creation>2025-08-21T09:53:04.563Z</creation></dates><accession>S-EPMC12280149</accession><cross_references><pubmed>40691217</pubmed><doi>10.1038/s41598-025-11820-2</doi></cross_references></HashMap>